Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution

Intensive Care Med. 2002 Nov;28(11):1664-7. doi: 10.1007/s00134-002-1495-z.

Abstract

Objective: To measure the sieving coefficient (SC) and clearance of vancomycin during high-volume haemofiltration (HVHF) and to evaluate the impact of different pre-dilution regimens on these variables.

Design and setting: Prospective interventional study in the intensive care unit in a tertiary university hospital.

Patients: Seven patients with septic shock and multi-organ dysfunction.

Interventions: HVHF (6 l/h fluid exchange) was performed in septic shock patients using variable proportions of their replacement fluid in pre- and post-dilution mode.

Measurements and results: Pre-filter, post-filter and ultrafiltrate vancomycin concentrations were measured simultaneously, and SC and clearance calculated. The measurements were repeated following each change in the proportion of pre-dilution fluid. SC steadily decreased as the proportion of pre-dilution decreased, changing from 0.76 in pure pre-dilution to 0.57 in pure post-dilution (p=0.0004). Clearance, however, increased with decreasing pre-dilution fluid rate, from 53.9 ml/min at pure pre-dilution to 67.2 ml/min at 2 l/h pre-dilution with 4 l/h post-dilution.

Conclusions: HVHF achieves high vancomycin clearances, which despite some deterioration in SC increase with the proportion of replacement fluid given post-filter. Clinicians applying HVHF need to be aware of such clearances to avoid inadequate vancomycin dosing and to adjust therapy according to variations in HVHF technique.

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / therapy
  • Aged
  • Anti-Bacterial Agents / pharmacokinetics*
  • Critical Illness
  • Cross-Over Studies
  • Female
  • Hemofiltration / methods*
  • Humans
  • Male
  • Middle Aged
  • Multiple Organ Failure / complications
  • Multiple Organ Failure / therapy*
  • Prospective Studies
  • Shock, Septic / complications
  • Shock, Septic / therapy*
  • Vancomycin / pharmacokinetics*

Substances

  • Anti-Bacterial Agents
  • Vancomycin